| 발생일자 |
2017.11.17 |
사건번호 |
1:17-cv-01672 |
| 법원국가 |
UNITED STATES OF AMERICA |
| 관할법원명 |
D.C.Delaware(지방법원) |
| 침해권리 |
특허 |
| 원고명 |
Genentech, Inc. / City of Hope
(
미국 /
외국기업
)
|
| 피고명 |
Pfizer, Inc.
(
미국 /
외국기업
)
|
| 소송유형 |
침해금지 |
| 분쟁내용 |
[Genentech, Inc. et al v. Pfizer, Inc.] 사건번호 1:17-cv-01672에 따르면 원고 Genentech, Inc./ City of Hope는 피고 Pfizer, Inc.을(를) 상대로 특허 US6121428|US6242177|US6331415|US6339142|US6407213|US6417335|US6489447|US6586206|US6610516|US6620918|US6627196|US6716602|US7371379|US7390660|US7449184|US7485704|US7501122|US7807799|US7846441|US7892549|US7923221|US7993834|US8044017|US8076066|US8314225|US8425908|US8440402|US8460895|US8512983|US8574869|US8633302|US8691232|US8710196|US8771988|US8822655|US9249218|US9428766|US9487809|US9493744|US9714293을(를) 침해하였다는 이유로 미국 델라웨어 지방법원에 소를 제기하였다. |
| 분쟁경과 |
진행중
|
| 산업분류 |
화학∙바이오
> 생명공학기술
|
| 계쟁제품 |
제안된 Genentech의 Herceptin® 제품의 바이오시밀러 버전 PF-05280014 - 일반 버전의 aBLA
[proposed biosimilar version of Genentech's Herceptin® product, PF-05280014 - Generic version of aBLA]
|
| 지재권번호/명칭 |
US6121428
|
Protein recovery
|
|
US6242177
|
Methods and compositions for secretion of heterologous polypeptides
|
|
US6331415
|
Methods of producing immunoglobulins, vectors and transformed host cells for use therein
|
|
US6339142
|
Protein purification
|
|
US6407213
|
Method for making humanized antibodies
|
|
US6417335
|
Protein purification
|
|
US6489447
|
Protein purification
|
|
US6586206
|
Methods for making recombinant proteins using apoptosis inhibitors
|
|
US6610516
|
Cell culture process
|
|
US6620918
|
Separation of polypeptide monomers
|
|
US6627196
|
Dosages for treatment with anti-ErbB2 antibodies
|
|
US6716602
|
Metabolic rate shifts in fermentations expressing recombinant proteins
|
|
US7371379
|
Dosages for treatment with anti-ErbB2 antibodies
|
|
US7390660
|
Methods for growing mammalian cells in vitro
|
|
US7449184
|
Fixed dosing of HER antibodies
|
|
US7485704
|
Reducing protein A leaching during protein A affinity chromatography
|
|
US7501122
|
Treatment with anti-ErbB2 antibody combinations
|
|
US7807799
|
Reducing protein A leaching during protein A affinity chromatography
|
|
US7846441
|
Treatment with anti-ErbB2 antibodies
|
|
US7892549
|
Treatment with anti-ErbB2 antibodies
|
|
US7923221
|
Methods of making antibody heavy and light chains having specificity for a desired antigen
|
|
US7993834
|
Detection of ErbB2 gene amplification to increase the likelihood of the effectiveness of ErbB2 antibody breast cancer therapy
|
|
US8044017
|
Protein purification
|
|
US8076066
|
Gene detection assay for improving the likelihood of an effective response to a HER2 antibody cancer therapy
|
|
US8314225
|
Heavy chain mutant leading to improved immunoglobulin production
|
|
US8425908
|
Treatment with anti-ErbB2 antibodies
|
|
US8440402
|
Gene detection assay for improving the likelihood of an effective response to a HER2 antibody cancer therapy
|
|
US8460895
|
Method for producing recombinant proteins with a constant content of pCO2 in the medium
|
|
US8512983
|
Production of proteins in glutamine-free cell culture media
|
|
US8574869
|
Prevention of disulfide bond reduction during recombinant production of polypeptides
|
|
US8633302
|
Variable tangential flow filtration
|
|
US8691232
|
Extending time to disease progression or survival in cancer patients
|
|
US8710196
|
Protein purification
|
|
US8771988
|
Protein expression from multiple nucleic acids
|
|
US8822655
|
Pre-filtration adjustment of buffer solutes
|
|
US9249218
|
Protein purification
|
|
US9428766
|
Protein expression from multiple nucleic acids
|
|
US9487809
|
Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
|
|
US9493744
|
Methods for viral inactivation and other adventitious agents
|
|
US9714293
|
Production of proteins in glutamine-free cell culture media
|
> 분쟁정보 > 지재권 분쟁동향 > 일일분쟁속보 (IP Daily)
해당 콘텐츠/상담 담당자
서울특별시 강남구 테헤란로 131 (역삼동, 한국지식재산센터 6층) 한국지식재산보호원 
